DLBCL
MCID: DFF005
MIFTS: 55

Diffuse Large B-Cell Lymphoma (DLBCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma 11 19 58 14 36 16 71 75 31
Dlbcl 11 19 58
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified 71 33
Dlbcl - [diffuse Large B-Cell Lymphoma] 33
Diffuse Large Beta Cell Lymphoma 33
Lymphoma, Large B-Cell, Diffuse 43
Large B-Cell Diffuse Lymphoma 75

Characteristics:


Inheritance:

Multigenic/multifactorial 58

Prevelance:

1-5/10000 (Europe) 1-9/100000 (France, Europe, Austria, Belgium, Bulgaria, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-9/1000000 (Croatia, Latvia) 58

Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0050745
MeSH 43 D016403
NCIt 49 C80280
ICD10 31 C83.3
MESH via Orphanet 44 D016403
ICD10 via Orphanet 32 C83.3
UMLS via Orphanet 72 C0079744
Orphanet 58 ORPHA544
UMLS 71 C0079744 C2699777

Summaries for Diffuse Large B-Cell Lymphoma

GARD: 19 Diffuse Large B-Cell Lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common blood cancer. Lymphomas occur when cells of the immune system, known as B lymphocytes, grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss.

MalaCards based summary: Diffuse Large B-Cell Lymphoma, also known as dlbcl, is related to burkitt lymphoma and lymphoma, non-hodgkin, familial. An important gene associated with Diffuse Large B-Cell Lymphoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involvement in the immune response in sepsis. The drugs Lomustine and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and breast.

Orphanet: 58 Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma (NHL; see this term) in adults characterized by a median age of presentation in the sixth decade of life (but also rarely occurring in adolescents and children) with the initial presentation being single or multiple rapidly growing masses (that may or may not be painful) in nodal or extranodal sites (such as thyroid, skin, breast, gastrointestinal tract, testes, bone, or brain) and that can be accompanied by symptoms of fever, night sweats and weight loss. DLBCL has an aggressive disease course, with the elderly having a poorer prognosis than younger patients, and with relapses being common.

Disease Ontology: 11 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Wikipedia: 75 Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible... more...

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases in the Diffuse Large B-Cell Lymphoma family:

Bn2 Diffuse Large B-Cell Lymphoma N1 Diffuse Large B-Cell Lymphoma
St2 Diffuse Large B-Cell Lymphoma A53 Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1129)
# Related Disease Score Top Affiliating Genes
1 burkitt lymphoma 33.4 MIR21 MIR17HG MIR155 MIR150 MIR145 MIR143
2 lymphoma, non-hodgkin, familial 32.7 MIR21 MIR17 MIR155 MIR151A MIR145 MIR143
3 leukemia, chronic lymphocytic 31.9 PEG10 MIR21 MIR17HG MIR17 MIR155 MIR151A
4 hematologic cancer 31.9 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
5 peripheral t-cell lymphoma 31.7 MIR21 MIR17 MIR155
6 immune deficiency disease 31.7 MIR210 MIR21 MIR17 MIR155 MIR150
7 peripheral nervous system disease 31.7 MIR21 MIR17 MIR151A MIR145 MIR143 MIR127
8 myeloma, multiple 31.6 MIR21 MIR17 MIR155 MIR145 HOTAIR
9 leukemia, acute lymphoblastic 31.6 MIR210 MIR21 MIR17 MIR155 MIR151A
10 leukemia, acute myeloid 31.6 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
11 mature t-cell and nk-cell lymphoma 31.5 MIR21 MIR17 MIR155
12 leukemia, chronic myeloid 31.4 MIR17 MIR155 MIR151A MIR127 HULC HOTAIR
13 primary cutaneous t-cell non-hodgkin lymphoma 31.3 MIR21 MIR17 MIR155
14 dermatomyositis 31.2 MIR210 MIR21 MIR155
15 brain cancer 31.2 MIR21 MIR17 MIR155 MIR145 MIR143
16 lymphatic system disease 31.1 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
17 rectal benign neoplasm 31.1 MIR17 MIR145 MIR143
18 t-cell acute lymphoblastic leukemia 31.1 MIR17 MIR155 MIR143 LUNAR1
19 nasopharyngeal carcinoma 31.1 MIR21 MIR17 MIR155 MIR151A MIR150 MIR145
20 central nervous system disease 31.1 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
21 rectum cancer 31.0 MIR21 MIR17 MIR150 MIR145 MIR143
22 colonic benign neoplasm 31.0 MIR21 MIR145 MIR143
23 nervous system disease 31.0 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
24 gastrointestinal system disease 31.0 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
25 polymyositis 31.0 MIR210 MIR21 MIR155 MIR127
26 connective tissue disease 31.0 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
27 lung cancer susceptibility 3 31.0 MIR21 MIR17 MIR150 MIR145 MIR143 HOTAIR
28 pancreatic cancer 31.0 MIR210 MIR21 MIR17 MIR155 MIR145 MIR143
29 bladder cancer 31.0 PANDAR MIR21 MIR17 MIR145 MIR143 MIR127
30 lung cancer 30.9 PANDAR MIR210 MIR21 MIR17HG MIR17 MIR155
31 high grade glioma 30.9 MIR21 MIR17 MIR155 MIR145 HULC HOTAIR
32 bone disease 30.9 MIR210 MIR21 MIR17 MIR155 MIR143 MIR127
33 pleural disease 30.9 MIR21 MIR17 MIR150
34 gallbladder cancer 30.8 MIR17 MIR145 MIR143 HOTAIR
35 myocardial infarction 30.8 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
36 ocular cancer 30.8 MIR21 MIR17 MIR155 MIR143
37 colorectal adenocarcinoma 30.7 MIR17 MIR145 MIR143
38 type 2 diabetes mellitus 30.7 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
39 renal cell carcinoma, nonpapillary 30.7 PANDAR MIR210 MIR21 MIR17 MIR155 MIR150
40 retinal disease 30.7 MIR210 MIR21 MIR17 MIR155
41 glioma 30.7 MIR210 MIR21 MIR17 HULC HOTAIR
42 arteries, anomalies of 30.6 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
43 cardiovascular system disease 30.6 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
44 gastric cancer 30.6 PANDAR MIR21 MIR17 MIR150 MIR145 MIR143
45 kidney cancer 30.6 MIR210 MIR21 MIR17 MIR150 MIR145 HOTAIR
46 lipoprotein quantitative trait locus 30.6 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
47 pancreatic ductal adenocarcinoma 30.6 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
48 lymphatic system cancer 30.6 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
49 gallbladder disease 30.5 MIR17 MIR145 MIR143
50 intestinal disease 30.5 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:



Diseases related to Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 358)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
2
Idarubicin Approved Phase 4 58957-92-9 42890
3
Rivoceranib Investigational Phase 4 811803-05-1 11315474
4 Mitogens Phase 4
5 Endothelial Growth Factors Phase 4
6 HIV Protease Inhibitors Phase 4
7 BB 1101 Phase 4
8
protease inhibitors Phase 4
9
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
10
Aldesleukin Approved Phase 3 110942-02-4
11
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
12
Coenzyme M Approved, Investigational Phase 3 3375-50-6 598 23662354
13
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
14
Pixantrone Approved, Investigational Phase 3 144510-96-3 134019
15
Vinblastine Approved Phase 3 865-21-4 241903 13342
16
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
19
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
20
Epirubicin Approved Phase 3 56420-45-2 41867
21
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
22
Sargramostim Approved, Investigational Phase 3 123774-72-1
23
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
24
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
25
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
26
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
27
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
28
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
29
Avelumab Approved, Investigational Phase 3 1537032-82-8
30
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
31
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
32
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
33
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
34
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
35
Bleomycin Approved, Investigational Phase 3 9041-93-4, 11056-06-7 5360373
36
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
37
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
38
Buformin Investigational, Withdrawn Phase 2, Phase 3 692-13-7 2468
39
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
40
Molgramostim Investigational Phase 3 99283-10-0
41
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
42 Interleukin-2 Phase 3
43 Analgesics, Non-Narcotic Phase 3
44 Analgesics Phase 3
45 Fluorodeoxyglucose F18 Phase 3
46
Epoetin Alfa Phase 3
47 Hematinics Phase 3
48 Cc-486 Phase 2, Phase 3
49 Vaccines Phase 3
50 Immunoglobulin Idiotypes Phase 3

Interventional clinical trials:

(show top 50) (show all 1161)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
3 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
4 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
6 B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) Recruiting NCT05518383 Phase 4 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
7 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Active, not recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
8 Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma Unknown status NCT03018626 Phase 3 Rituximab;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Vindesine;Bleomycin
9 Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma Unknown status NCT02767674 Phase 3 Rituximab;Gemcitabine;Oxaliplatin;Cyclophosphamide;Epirubicin Injectable Product;Vindesine;Prednisone
10 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
11 An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients Unknown status NCT03318835 Phase 3 Thalidomide combined with R-CHOP;R-CHOP
12 Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) Unknown status NCT03777085 Phase 3 TQB2303;Rituximab
13 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;VP-16
14 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
15 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Unknown status NCT02777736 Phase 3 Methotrexate
16 Prospective, Multicenter, Randomized ,Open-labeled, Phase III Study Comparing High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for the Prophylaxis of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma Unknown status NCT03123718 Phase 3 Intrathecal methotrexate;High-dose intravenous methotrexate
17 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
18 Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study Unknown status NCT02428751 Phase 3 Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
19 Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03229616 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
20 A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients Unknown status NCT03650933 Phase 3
21 Cinobufacini Tablets Combined With R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone)/CHOP in Treatment of Diffuse Large B Cell Lymphoma: A Phase II Randomized, Controlled and Multi-center Study Unknown status NCT02871869 Phase 2, Phase 3 vindesine;cyclophosphamide;Epirubicin;prednisone tablets;Cinobufacini Tablets;Rituximab
22 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
23 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
24 A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients Unknown status NCT02772822 Phase 3 SCT400 plus CHOP;Rituximab plus CHOP
25 A Phase III, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of SIBP-02 (Rituximab Biosimilar) and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL Unknown status NCT04361279 Phase 3 SIBP-02;Rituximab
26 A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT,in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL Unknown status NCT03213977 Phase 3 R-DA-EPOCH;R-DA-EPOCH + auto-HSCT;R-CEOP90;R-CEOP90 + auto-HSCT
27 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
28 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
29 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Completed NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
30 Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association Completed NCT02128061 Phase 3 Lenalidomide;Rituximab
31 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma Completed NCT00491491 Phase 3 ibritumomab tiuxetan
32 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Completed NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
33 Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma Completed NCT02285062 Phase 3 lenalidomide;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;prednisone;vincristine
34 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
35 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Completed NCT04236141 Phase 3 Polatuzumab Vedotin;Bendamustine;Rituximab;Placebo
36 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3
37 Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma. Completed NCT01987505 Phase 3 Rituximab
38 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed NCT01855750 Phase 3 Ibrutinib;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone (or equivalent)
39 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
40 Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1. Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
41 Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma. Completed NCT00144755 Phase 3 Darbepoetin alfa
42 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
43 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ Completed NCT03263026 Phase 3 Enzastaurin Hydrochloride
44 Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
45 Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Cytarabine;Melphalan
46 A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan]
47 A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma Completed NCT03372837 Phase 3 Rituximab
48 A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01148446 Phase 3 Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
49 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
50 A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, large b-cell, diffuse

Genetic Tests for Diffuse Large B-Cell Lymphoma

Anatomical Context for Diffuse Large B-Cell Lymphoma

Organs/tissues related to Diffuse Large B-Cell Lymphoma:

MalaCards : B Cells, T Cells, Breast, Thyroid, Bone, Testes, Bone Marrow

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 16526)
# Title Authors PMID Year
1
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. 62 46
19287466 2009
2
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 62 46
18537969 2008
3
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. 62 46
18318758 2008
4
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. 62 46
17487835 2007
5
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. 62 46
16041695 2005
6
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. 62 46
15738415 2005
7
Downregulation of microRNAs-143 and -145 in B-cell malignancies. 46
17892514 2007
8
MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. 46
16675453 2006
9
Total Knee Arthroplasty Complicated by Diffuse Large B-Cell Lymphoma. 62
36465694 2023
10
Hemophagocytic lymphohistiocytosis secondary to diffuse large B-cell lymphoma presenting with recurrent multi-territory infarcts: A case report. 62
36411855 2023
11
Potential Role of 68Ga-NOTA-Duramycin PET/CT Imaging for Early Response Evaluation in a Lymphoma Patient: A Case Report. 62
36469075 2023
12
Poly zinc finger protein ZFP14 suppresses lymphomagenesis and abnormal inflammatory response via the HOXA gene cluster. 62
36349645 2023
13
Multi-scale feature similarity-based weakly supervised lymphoma segmentation in PET/CT images. 62
36306574 2022
14
TBL1X: At the crossroads of transcriptional and posttranscriptional regulation. 62
36206873 2022
15
The dual role of CD70 in B-cell lymphomagenesis. 62
36471481 2022
16
Biological and clinical significance of epigenetic alterations in B-cell lymphomas. 62
36208393 2022
17
18 F-FDG Whole-Body PET-MR in Primary Hepatic Lymphoma Mimicking Focal Nodular Hyperplasia. 62
36398300 2022
18
Characteristics and Outcomes of Alberta Lymphoma Patients with a History of Immunosuppressive therapy for Autoimmune Conditions. 62
36031543 2022
19
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. 62
36174934 2022
20
18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients. 62
35710733 2022
21
Top advances in lymphoma for 2021. 62
36201139 2022
22
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study. 62
36453136 2022
23
Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan. 62
36470790 2022
24
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. 62
36369950 2022
25
Comparison of pyrrolobenzodiazepine dimer bis-imine versus mono-imine: DNA interstrand cross-linking, cytotoxicity, and antibody-drug conjugate efficacy and toxicity. 62
36474428 2022
26
Follicular lymphoma: 2023 update on diagnosis and management. 62
36255040 2022
27
Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies. 62
36367044 2022
28
Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12. 62
36191884 2022
29
Genome wide exploration of the methylome in aggressive B-cell lymphoma in Golden Retrievers reveals a conserved hypermethylome. 62
35912844 2022
30
Epidemiological features for primary lymphoma of the female genital tract patients and development of a nomogram to predict survival. 62
35416104 2022
31
Prognostic role of controlling nutritional status score in hematological malignancies. 62
35622088 2022
32
SLP76 Mutation Associated with Combined Immunodeficiency and EBV-Related Lymphoma. 62
36474126 2022
33
Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. 62
35895386 2022
34
Circulating Tumor DNA in Lymphoma. 62
36214943 2022
35
Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. 62
36109172 2022
36
Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel. 62
36116729 2022
37
Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study. 62
36040107 2022
38
Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities. 62
36459219 2022
39
Diffuse Large B-Cell Lymphoma in the Public-Sector of Johannesburg, South Africa, in the Era of Widescale Antiretroviral Therapy Use. 62
35916644 2022
40
Herbicide use in farming and other jobs in relation to non-Hodgkin's lymphoma (NHL) risk. 62
36207110 2022
41
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. 62
35815677 2022
42
B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers. 62
36166198 2022
43
Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition. 62
36435066 2022
44
Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. 62
36252471 2022
45
Ocular recurrence of diffuse large B-cell lymphoma originating from central nervous system: A case report. 62
35750610 2022
46
Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis. 62
35754389 2022
47
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience 62
35657203 2022
48
Outcomes of high‑dose methotrexate for CNS prophylaxis in diffuse large B‑cell lymphoma with an intermediate or high CNS‑International Prognostic Index: A single‑center retrospective cohort study. 62
36338604 2022
49
CAPG facilitates diffuse large B-cell lymphoma cell progression through PI3K/AKT signaling pathway. 62
36244872 2022
50
[New European approval: Polatuzumab vedotin associated to rituximab, cyclophosphamide, doxorubicin and prednisone in previously untreated Diffuse Large B-Cell Lymphoma]. 62
36441028 2022

Variations for Diffuse Large B-Cell Lymphoma

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

6 (show top 50) (show all 118)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13828 1 1 84900000 Loss Diffuse large b-cell lymphoma
2 17406 1 142600000 249250621 Gain Diffuse large b-cell lymphoma
3 20082 1 15300000 163800000 Gain Diffuse large b-cell lymphoma
4 38345 10 101900000 103000000 Gain Diffuse large b-cell lymphoma
5 38773 10 104900000 105800000 Gain Diffuse large b-cell lymphoma
6 38901 10 105800000 121700000 Loss Diffuse large b-cell lymphoma
7 40597 10 130600000 135534747 Loss Diffuse large b-cell lymphoma
8 43294 10 46100000 64500000 Loss Diffuse large b-cell lymphoma
9 48479 11 1 43500000 Gain Diffuse large b-cell lymphoma
10 51204 11 123900000 135006516 Loss Diffuse large b-cell lymphoma
11 53206 11 26100000 36400000 Loss Diffuse large b-cell lymphoma
12 55792 11 55700000 135006516 Gain Diffuse large b-cell lymphoma
13 64291 12 12600000 14800000 Gain CDKN1B Diffuse large b-cell lymphoma
14 70914 12 66000000 69800000 Gain MDM2 Diffuse large b-cell lymphoma
15 74343 13 104800000 110300000 Loss Diffuse large b-cell lymphoma
16 74383 13 105800000 109100000 Loss Diffuse large b-cell lymphoma
17 75387 13 19500000 55300000 Gain Diffuse large b-cell lymphoma
18 76712 13 35500000 75400000 Loss Diffuse large b-cell lymphoma
19 79280 13 68600000 115169878 Gain Diffuse large b-cell lymphoma
20 86223 14 55800000 61200000 Loss Diffuse large b-cell lymphoma
21 88116 14 84900000 107349540 Loss Diffuse large b-cell lymphoma
22 90236 15 20700000 102531392 Loss Diffuse large b-cell lymphoma
23 97251 16 1 34600000 Gain Diffuse large b-cell lymphoma
24 97373 16 1 7900000 Gain ABCA3 Diffuse large b-cell lymphoma
25 97375 16 1 7900000 Gain ECI1 Diffuse large b-cell lymphoma
26 97377 16 1 7900000 Gain E4F1 Diffuse large b-cell lymphoma
27 97379 16 1 7900000 Gain HAGH Diffuse large b-cell lymphoma
28 97381 16 1 7900000 Gain IGFALS Diffuse large b-cell lymphoma
29 97383 16 1 7900000 Gain MRPS34 Diffuse large b-cell lymphoma
30 97385 16 1 7900000 Gain NME3 Diffuse large b-cell lymphoma
31 97387 16 1 7900000 Gain NUBP2 Diffuse large b-cell lymphoma
32 97391 16 1 7900000 Gain RNPS1 Diffuse large b-cell lymphoma
33 99692 16 28100000 36600000 Loss Diffuse large b-cell lymphoma
34 102840 16 57400000 90354753 Gain Diffuse large b-cell lymphoma
35 102843 16 57400000 90354753 Loss Diffuse large b-cell lymphoma
36 104071 16 66700000 70800000 Gain DDX19B Diffuse large b-cell lymphoma
37 104073 16 66700000 70800000 Gain FCSK Diffuse large b-cell lymphoma
38 104075 16 66700000 70800000 Gain ST3GAL2 Diffuse large b-cell lymphoma
39 106530 16 88700000 90354753 Gain Diffuse large b-cell lymphoma
40 106806 17 1 22200000 Loss Diffuse large b-cell lymphoma
41 111431 17 3600000 6800000 Loss TP53 Diffuse large b-cell lymphoma
42 120634 18 2900000 78077248 Gain Diffuse large b-cell lymphoma
43 121454 18 43500000 48200000 Gain Diffuse large b-cell lymphoma
44 121719 18 46400000 52000000 Gain BCL2 Diffuse large b-cell lymphoma
45 122173 18 53800000 56200000 Gain MALT1 Diffuse large b-cell lymphoma
46 123098 18 66800000 68700000 Loss Diffuse large b-cell lymphoma
47 123108 18 66900000 71300000 Gain Diffuse large b-cell lymphoma
48 127687 19 35500000 38300000 Gain KIRREL2 Diffuse large b-cell lymphoma
49 127689 19 35500000 38300000 Gain KMT2B Diffuse large b-cell lymphoma
50 127691 19 35500000 38300000 Gain NPHS1 Diffuse large b-cell lymphoma

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.25 MIR17 MIR155 MIR150 MIR145 MIR143
2 11.12 MIR21 MIR155 MIR145
3 10.85 MIR210 MIR21 MIR17 MIR145 MIR143

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.58 MIR210 MIR21 MIR17HG MIR17 MIR155 MIR150

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 9.6 MIR210 MIR21 MIR17HG MIR17 MIR155 MIR151A
2 angiotensin-activated signaling pathway GO:0038166 9.49 MIR145 MIR143
3 aorta smooth muscle tissue morphogenesis GO:0060414 9.48 MIR145 MIR143
4 positive regulation of metalloendopeptidase activity GO:1904685 9.46 MIR21 MIR17
5 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.46 MIR210 MIR21 MIR17 MIR145
6 negative regulation of BMP secretion GO:2001285 9.43 MIR210 MIR17
7 regulation of phenotypic switching GO:1900239 9.4 MIR145 MIR143
8 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.37 MIR17 MIR143
9 positive regulation of cellular response to hypoxia GO:1900039 9.32 MIR21 MIR145
10 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR145 MIR143
11 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.13 MIR17 MIR21 MIR210

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.56 MIR210 MIR21 MIR17 MIR155 MIR151A MIR145
2 mRNA base-pairing translational repressor activity GO:1903231 9.28 MIR210 MIR21 MIR17 MIR155 MIR151A MIR150

Sources for Diffuse Large B-Cell Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....